Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems
- PMID: 37916706
- PMCID: PMC10734317
- DOI: 10.57264/cer-2023-0023
Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems
Abstract
Aim: This study was designed to recommend strategies to improve prostate patients' access to radiotherapy treatment in the Brazilian Unified Health System, along with a cost-tool to support radiotherapy care pathways' lead times and costs. Methods: Data was collected prospectively from patients with prostate cancer receiving radiotherapy in two Brazilian centers to provide data to apply design thinking and process reengineering techniques. The current status of the radiotherapy pathway was determined and the length of time taken for in-hospital activities was measured using data exported from ARIA®. Interviews with patients were used to estimate their waiting periods. This provided the data used to provide recommended strategies and the cost tool based on time-driven activity-based costing. The strategies were classified according to priority. Results: Data from 47 patients were analyzed. The mean interval from diagnosis to start of radiotherapy was 349 days (SD581), and the mean interval from seeking medical attention to starting treatment was 635 days (SD629). Twelve strategies affecting in-hospital processes and 11 impacting patients' care pathways and experiences are recommended, mostly focused on system improvement opportunities. A time-driven activity-based costing monitoring using data extracted from ARIA was coded and can be used by centers as a cost assessment guide. Conclusion: This study uses reengineering and design techniques to introduce priority strategies to allow more efficient and patient-centered radiotherapy.
Keywords: costs; design thinking; prostate cancer; radiotherapy; value-based healthcare.
Conflict of interest statement
Competing interest disclosure
The authors have no financial and/or nonfinancial competing interests or relevant affiliations with any organization/entity to declare that are relevant to the subject matter or materials discussed in this manuscript. This includes employment, grants or research funding, consultancies, membership on scientific or other advisory boards, honoraria, stock ownership or options, paid expert testimony, patents received or pending, or royalties.
Figures
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). - PubMed
-
- Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil. INCA, Brazil, p120 (2019).
-
- DATASUS. Painel Oncologia. http://tabnet.datasus.gov.br/cgi/dhdat.exe?PAINEL_ONCO/PAINEL_ONCOLOGIAB... (Accessed: 10 August 2022).
-
- DATASUS. Mortalidade – desde 1996 pela CID-10. https://datasus.saude.gov.br/mortalidade-desde-1996-pela-cid-10 (Accessed: 10 August 2022).
-
- Horwich A, Hugosson J, de Reijke T et al. Prostate cancer: ESMO consensus conference guidelines 2012. Ann. Oncol. 24(5), 1141–1162 (2013). - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical